Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Greenberger

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
Molecular Cancer Therapeutics|October 17, 2006
Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitorJennifer A Seamon, Catherine A Rugg, Stuart Emanuel, et al.
Angiogenesis|June 23, 2009
A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivoKenneth R LaMontagne, Jeannene Butler, Virna B Borowski, et al.
Endocrinology|May 8, 2004
Identification and validation of novel androgen-regulated genes in prostate cancerAnne Marie Velasco, Kimberly A Gillis, Yizheng Li, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2007
Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitorsRonghui Lin, George Chiu, Yang Yu, et al.
Bioconjugate Chemistry|March 17, 2005
An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistancePhilip R Hamann, Lois M Hinman, Carl F Beyer, et al.
Bioconjugate Chemistry|March 29, 2008
Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkersHong Zhao, Belen Rubio, Puja Sapra, et al.
Bioorganic & Medicinal Chemistry Letters|July 21, 2004
D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitorsArie Zask, Gary Birnberg, Katherine Cheung, et al.
Oncology Research|January 1, 1996
alpha-(3,4-dimethyoxyphenyl)-3,4-dihydro-6,7-dimethoxy-alpha- [(4-methylphenyl)thio]-2(1H)-isoquinolineheptanenitrile (CL 329,753): a novel chemosensitizing agent for P-glycoprotein-mediated resistance with improved biological properties compared with verapamil and cyclosporine AL M Greenberger, K I Collins, T Annable, et al.
Biochemical Pharmacology|January 9, 1992
Biochemical and genetic characterization of the multidrug resistance phenotype in murine macrophage-like J774.2 cellsL S Kirschner, L M Greenberger, S I Hsu, et al.
Molecular Cancer Therapeutics|February 12, 2013
Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal modelsYaming Wu, Yixian Zhang, Maoliang Wang, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
Molecular Cancer Therapeutics|October 17, 2006
Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitorJennifer A Seamon, Catherine A Rugg, Stuart Emanuel, et al.
Angiogenesis|June 23, 2009
A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivoKenneth R LaMontagne, Jeannene Butler, Virna B Borowski, et al.
Endocrinology|May 8, 2004
Identification and validation of novel androgen-regulated genes in prostate cancerAnne Marie Velasco, Kimberly A Gillis, Yizheng Li, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2007
Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitorsRonghui Lin, George Chiu, Yang Yu, et al.
Bioconjugate Chemistry|March 17, 2005
An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistancePhilip R Hamann, Lois M Hinman, Carl F Beyer, et al.
Bioconjugate Chemistry|March 29, 2008
Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkersHong Zhao, Belen Rubio, Puja Sapra, et al.
Bioorganic & Medicinal Chemistry Letters|July 21, 2004
D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitorsArie Zask, Gary Birnberg, Katherine Cheung, et al.
Oncology Research|January 1, 1996
alpha-(3,4-dimethyoxyphenyl)-3,4-dihydro-6,7-dimethoxy-alpha- [(4-methylphenyl)thio]-2(1H)-isoquinolineheptanenitrile (CL 329,753): a novel chemosensitizing agent for P-glycoprotein-mediated resistance with improved biological properties compared with verapamil and cyclosporine AL M Greenberger, K I Collins, T Annable, et al.
Biochemical Pharmacology|January 9, 1992
Biochemical and genetic characterization of the multidrug resistance phenotype in murine macrophage-like J774.2 cellsL S Kirschner, L M Greenberger, S I Hsu, et al.
Molecular Cancer Therapeutics|February 12, 2013
Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal modelsYaming Wu, Yixian Zhang, Maoliang Wang, et al.
Pageof 10